467-55-0
中文名称
海柯吉宁
英文名称
Hecogenin
CAS
467-55-0
EINECS 编号
207-392-4
分子式
C27H42O4
MDL 编号
MFCD00067285
分子量
430.62
MOL 文件
467-55-0.mol
更新日期
2025/05/14 11:27:18
467-55-0 结构式
基本信息
中文别名
海柯吉宁海柯皂甙元
海柯皂苷元
(25R)-5α-螺甾(烷)-3β-醇-12-酮
(3β,5α,25R)-3-羟基螺甾(烷)-12-酮
海可吉宁
番麻皂素
辛酸己酯
核柯配基
海可吉宁 (25R)-5Α-螺甾(烷)-3Β-醇-12-酮
蕃麻皂甙元
蕃麻皂素
英文别名
25R,5ALPHA-SPIROSTAN-3BETA-OL-12-ONE3BETA-HYDROXY-5ALPHA-SPIROSTAN-12-ONE
5-ALPHA, 20-ALPHA, 22-ALPHA, 25D-SPIROSTAN-3-BETA-OL-12-ONE
5ALPHA-SPIROSTAN-3BETA-OL-12-ONE
HECOGENIN
(25R)-5-Spirostan-3-ol-12-one
Hecoginin
HECOGENIN 98.0% BY HPLC
(3,5,25R)-3-Hydroxysiprostan-1
(3,5,25R)-3-Hydroxysiprostan-12-one
HECOGENIN (3B-HYDROXY-5A-SPIROSTAN-12-ONE)
3β-Hydroxy-5α-spirostan-12-one, 5α-Spirostan-3β-ol-12-one
12-Oxotigogenin
3-b-Hydroxy-5-a-spirostan-12-one
(25R)-3β-Hydroxy-5α-spirostan-12-one
所属类别
生物化工：提取物物理化学性质
外观性状结晶化合物（丙酮）。熔点 264-266℃。（有报道称具三种晶形，熔点 245℃，253℃，268℃）[α]D+8°（氯仿）/-10°（二烷）。
熔点268°C
比旋光度7.2 º (c=0.8 g/100ml, CHCl3)
沸点464.85°C (rough estimate)
密度1.0040 (rough estimate)
折射率1.4840 (estimate)
储存条件Sealed in dry,Room Temperature
溶解度可溶于氯仿（少许）、甲醇（少许）
酸度系数(pKa)15.10±0.70(Predicted)
形态固体
颜色白色至灰白色
Merck4622
海柯吉宁价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/02/08 | HY-N1422 | 海柯吉宁 Hecogenin | 467-55-0 | 5mg | 171元 |
| 2025/02/08 | HY-N1422 | 海柯吉宁 Hecogenin | 467-55-0 | 10mg | 246元 |
| 2025/02/08 | HY-N1422 | 海柯吉宁 Hecogenin | 467-55-0 | 25 mg | 433元 |
常见问题列表
生物活性
Hecogenin 是从龙舌兰 (Agave sisalana) 分离的类固醇皂苷，是人 UDP-葡萄糖醛酸糖基转移酶的选择性抑制剂。Hecogenin 具有广泛的药理活性，包括抗炎，抗真菌和胃保护作用。靶点
| Target | Value |
|
UGT1A4
() | 1.5 μM |
体内研究
Hecogenin (3.1-90 mg/kg; oral administration; for 15 hours; male Swiss mice) acutely administered, before ethanol, exhibits a potent gastroprotective effect. The Hecogenin pretreatment normalizes GSH levels and significantly reduces lipid peroxidation and nitrite levels in the stomach, as evaluated by the ethanol-induced gastric lesion model. Hecogenin also decreases MPO release and significantly protects the gastric mucosa.
| Animal Model: | Male Swiss mice (20-30 g) with ethanol |
| Dosage: | 3.1 mg/kg, 7.5 mg/kg, 15 mg/kg, 30 mg/kg, 60 mg/kg and 90 mg/kg |
| Administration: | Oral administration; for 15 hours |
| Result: | Normalized GSH levels and significantly reduced lipid peroxidation and nitrite levels in the stomach, as evaluated by the ethanol-induced gastric lesion model. Decreased MPO release and significantly protected the gastric mucosa. |